| 摘要 |
PROBLEM TO BE SOLVED: To provide a medicine improving corneal sensitivity decrease caused by corneal operations such as laser-assisted in situ keratomileusis (LASIK) or cataract operation, corneal sensitivity decrease caused by corneal degeneration, and dry eye symptom caused thereby. SOLUTION: A corneal neurite formation promotor, a corneal sensitivity improver and a dry eye therapeutic agent, which are characterized by containing lysophosphatidic acid (LPA) receptor antagonist, are provided. COPYRIGHT: (C)2006,JPO&NCIPI
|
